Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods [PDF]
Frontiers in PharmacologyBackgroundThe stimulation and activation of soluble guanylate cyclase (sGC) has been a prominent focus of study in recent years. Currently, sGC stimulators/activators have a wide range of applications in various fields.
Bing Ju Yan +3 more
exaly +4 more sources
Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction [PDF]
Egyptian Heart JournalBackground Soluble guanylate cyclase (sGC) stimulators have been investigated for heart failure (HF) in several randomized controlled trials (RCTs). However, its place in the management guidelines of either HFrEF or HfpEF is still inconclusive.
Mohamed Abuelazm +2 more
exaly +3 more sources
Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021 [PDF]
Frontiers in Pharmacology, 2022 Background: Several studies have shown that soluble guanylate cyclase (sGC) stimulators have cardiovascular (CV) benefits. However, few bibliometric analyses have examined this field systematically.
Xiao-Yan Jia +5 more
doaj +2 more sources
Efficacy and safety of soluble guanylate cyclase stimulators or activators for chronic kidney disease: a systematic review and meta-analysis [PDF]
Frontiers in MedicineBackgroundChronic Kidney Disease (CKD) poses a major global health burden, leading to serious complications and death. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling axis regulates various kidney ...
Jiaying Zhang, Xin Li, Xiaofeng Yu
doaj +2 more sources
Soluble guanylate cyclase stimulators and activators: new horizons in the treatment of priapism associated with sickle cell disease [PDF]
Frontiers in PharmacologyPriapism, defined as a prolonged and often painful penile erection occurring without sexual stimulation or desire, is a common complication in sickle cell disease (SCD), affecting up to 48% of male patients.
Dalila Andrade Pereira +3 more
doaj +2 more sources
Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress [PDF]
Frontiers in Pharmacology, 2012 Soluble guanylate cyclase (sGC), the primary mediator of nitric oxide (NO) bioactivity, exists as reduced (NO-sensitive) and oxidized (NO-insensitive) forms.
Melissa H Costell +21 more
doaj +2 more sources
ESC Heart FailureAims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF.
Veraprapas Kittipibul +13 more
doaj +2 more sources
Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure [PDF]
CellsThe recent advancements in the medical management of patients with chronic heart failure with reduced ejection fraction (HFrEF) is the soluble guanylate cyclase (sGC) stimulator, vericiguat.
Tine Bajec, Gregor Poglajen
doaj +2 more sources
Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways [PDF]
BiomedicinesBackground/Objectives: Pulmonary hypertension is a progressive disease leading to right heart failure. One treatment strategy is to induce vasodilation via the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) signaling ...
Katharina Nubbemeyer +6 more
doaj +2 more sources
Soluble guanylate cyclase modulators—a novel therapeutic approach for diabetic kidney disease [PDF]
Renal FailureDiabetic kidney disease (DKD) is a common complication, affecting approximately 40% of patients with diabetes and imposing substantial health and economic burdens worldwide.
Yuqing Xu +8 more
doaj +2 more sources